These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 3133943

  • 1. A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer.
    Waxman J.
    Am J Clin Oncol; 1988; 11 Suppl 1():S16-8. PubMed ID: 3133943
    [Abstract] [Full Text] [Related]

  • 2. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH, Hendry WF, Whitfield HN, Oliver RT.
    Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T, Kishimoto T, Shimazaki J, Yoshida O, Isurugi K.
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [Abstract] [Full Text] [Related]

  • 4. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983 Jul; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

  • 5. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP, Delavault P, Blumberg J.
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
    Sandow J, von Rechenberg W, Engelbart K.
    Am J Clin Oncol; 1988 Oct; 11 Suppl 1():S6-10. PubMed ID: 3291602
    [Abstract] [Full Text] [Related]

  • 7. The first clinical use of depot buserelin for advanced prostatic carcinoma.
    Waxman JH, Sandow J, Man A, Barnett MJ, Hendry WF, Besser GM, Oliver RT, Magill PJ.
    Cancer Chemother Pharmacol; 1986 Oct; 18(2):174-5. PubMed ID: 3098445
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS.
    Am J Clin Oncol; 1988 Oct; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [Abstract] [Full Text] [Related]

  • 9. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B, Varenhorst E, Petas A, Sandow J.
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [Abstract] [Full Text] [Related]

  • 10. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Jacobi GH, Wenderoth UK, Ehrenthal W, von Wallenberg H, Spindler HW, Hohenfellner R.
    Am J Clin Oncol; 1988 Sep; 11 Suppl 1():S36-43. PubMed ID: 2968761
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK, Jacobi GH.
    Ann Urol (Paris); 1986 Sep; 20(2):95-7. PubMed ID: 3087269
    [Abstract] [Full Text] [Related]

  • 12. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK, Jacobi GH.
    Prog Clin Biol Res; 1985 Sep; 185A():297-305. PubMed ID: 3162176
    [Abstract] [Full Text] [Related]

  • 13. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
    Nagel R, Borgmann V, Al-Abadi H, Schmidt-Gollwitzer M.
    J Urol (Paris); 1983 Sep; 89(9):669-76. PubMed ID: 6425419
    [Abstract] [Full Text] [Related]

  • 14. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK, Spindler HW, Ehrenthal W, von Wallenberg H, Happ J, Jacobi GH.
    Prog Clin Biol Res; 1987 Sep; 243A():207-20. PubMed ID: 2958851
    [No Abstract] [Full Text] [Related]

  • 15. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G.
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [Abstract] [Full Text] [Related]

  • 16. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
    Waxman J.
    Prog Clin Biol Res; 1989 Jun; 303():61-8. PubMed ID: 2528741
    [No Abstract] [Full Text] [Related]

  • 17. The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents.
    de Voogt HJ, Adenauer H, Widdra WG.
    Scand J Urol Nephrol Suppl; 1991 Jun; 138():131-6. PubMed ID: 1838426
    [Abstract] [Full Text] [Related]

  • 18. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J, Ruutu M, Juusela H, Hansson E, Permi J.
    Ann Chir Gynaecol Suppl; 1993 Jun; 206():5-8. PubMed ID: 8291869
    [Abstract] [Full Text] [Related]

  • 19. Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer.
    Waxman JH, Sandow J, Abel P, Farah N, O'Donoghue EP, Fleming J, Cox J, Sikora K, Williams G.
    Acta Endocrinol (Copenh); 1989 Mar; 120(3):315-8. PubMed ID: 2494825
    [Abstract] [Full Text] [Related]

  • 20. Three-monthly GnRH agonist (buserelin) for prostatic cancer.
    Waxman J, Sandow J, Abel P, Barton C, Keane P, Williams G.
    Br J Urol; 1990 Jan; 65(1):43-5. PubMed ID: 2107012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.